Esperion Therapeutics【0IIM】銘柄情報

Esperion Therapeutics Inc (0IIM) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

37.89

( - )

買値

37.89

売値

37.89

出来高

48,089

平均取引量 (3 か月)

US$ 13,223,526

財務取引量

0.00 日の範囲 0.00

37.89 52 週間の範囲 37.89

時価総額

9.754B

企業価値

1.201B

前日終値

37.89

始値

時刻

500

3.1594

(O)

最終取引時間

VWAP

歳入

418.24M

純利益

-7.42M

発行済株式数

257,431,942

浮動株比率 (%)

90.98%

機関投資家保有比率 (%)

76.42%

配当利回り

PER

-94.37

株価売上高倍率 (PSR)

1.95

1 株当たり利益 (EPS)

-0.03

ベータ

1.06

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid... Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. 詳細を表示

セクター

業界

ウェブサイト

www.esperion.com

本社

Ann Arbor, United States

設立

2026

Esperion Therapeutics Inc is listed in the sector of the ロンドン証券取引所 with ticker 0IIM. The last closing price for Esperion Therapeutics was US$37.89. Over the last year, Esperion Therapeutics shares have traded in a share price range of US$ 37.89 to US$ 37.89.

Esperion Therapeutics currently has 257,431,942 shares in issue. The market capitalisation of Esperion Therapeutics is US$9.75 billion. Esperion Therapeutics has a price to earnings ratio (PE ratio) of -94.37.

Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowe...

Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	37.89	37.89	37.89	41979	37.89	DE
52	37.89	37.89	37.89	32473	37.89	DE
156	37.89	37.89	37.89	20729	37.89	DE
260	37.89	37.89	37.89	12512	37.89	DE